dc.contributor.author | Sharpe, E | |
dc.contributor.author | Hoey, R | |
dc.contributor.author | Yap, C | |
dc.contributor.author | Workman, P | |
dc.date.accessioned | 2020-02-19T09:34:13Z | |
dc.date.issued | 2020-09-01 | |
dc.identifier.citation | Drug discovery today, 2020, 25 (9), pp. 1561 - 1568 | |
dc.identifier.issn | 1359-6446 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3511 | |
dc.identifier.eissn | 1878-5832 | |
dc.identifier.doi | 10.1016/j.drudis.2020.01.004 | |
dc.description.abstract | Analysis of cancer drugs licensed through the European Medicines Agency (EMA) in 2000-2016 shows that the number of authorisations increased over that timeframe. The median number of licensed drugs each year rose from six for 2000-2008 to 13.5 for 2009-2016. Over 2000-2016, there were 64 drug authorisations for haematological, 15 for breast, and 12 for skin cancer, but none for oesophageal, brain, bladder, or uterine cancer. Only 6% of authorisations included a paediatric indication. The average time for a drug to progress from patent priority date to availability on the National Health Service (NHS) increased from 12.8 years for drugs first licensed in 2000-2008 to 14.0 years for those licensed in 2009-2016. There was evidence that the most innovative drugs were not being prioritised for EMA licensing and NICE approval. | |
dc.format | Print-Electronic | |
dc.format.extent | 1561 - 1568 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCI LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | From patent to patient: analysing access to innovative cancer drugs. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-01-15 | |
rioxxterms.versionofrecord | 10.1016/j.drudis.2020.01.004 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Drug discovery today | |
pubs.issue | 9 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Published | |
pubs.volume | 25 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Clinical Trials & Statistics Unit | |
dc.contributor.icrauthor | Yap, Christina | |
dc.contributor.icrauthor | Workman, Paul | |